XT
PMCB icon

XTX Topco’s PharmaCyte Biotech PMCB Stock Holding History

XTX Topco’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.3K Sell
34,180
-18,182
-35% -$13.7K ﹤0.01% 3854
2026
Q1 		$34.8K Buy
52,362
+27,920
+114% +$21.4K ﹤0.01% 3415
2025
Q4 		$17.7K Buy
+24,442
New +$22K ﹤0.01% 3083

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

XTX Topco's PMCB Position: Q2 2026 in Review

XTX Topco reduced its PharmaCyte Biotech (PMCB) stake by 35% in Q2 2026, selling an estimated $13.7K and leaving 34,180 shares worth $26.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3854.

XTX Topco first reported a position in PMCB in Q4 2025 and has held it in 3 quarters since. The position peaked at $34.8K in Q1 2026. 28 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • XTX Topco held 34,180 shares of PharmaCyte Biotech worth $26.3K as of Q2 2026.
  • XTX Topco sold 18,182 PharmaCyte Biotech shares in Q2 2026, an estimated $13.7K.
  • PharmaCyte Biotech made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3854 holding.
  • XTX Topco first reported a position in PharmaCyte Biotech in Q4 2025 and has held it in 3 quarters since.
  • XTX Topco's PharmaCyte Biotech position peaked at $34.8K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.